Abstract:

This review article examines the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiovascular (CV) outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The SGLT2 inhibitors, while being developed for type 2 diabetes management, are showing great promise in reducing hospitalization for heart failure and major adverse cardiovascular events: benefits shown in major trials like Dapagliflozin in patients with Heart failure and reduced Ejection fraction (DAPA-HF) and Empagliflozin outcome trial in patients with chronic Heart Failure and a Reduced Ejection fraction (EMPEROR-Reduced). The review underlines the therapeutic implications of SGLT2 inhibitors in both diabetic and nondiabetic patients with HFrEF for improving survival rates, the risk of hospitalization, and renal function preservation. These trials had an in-depth methodology and results review, after which a discussion on the clinical implications took place to decide on the wide application of SGLT2 inhibitors in managing HFrEF independent of their diabetes status.

References:

[1].   Starr, J. A., Pinner, N. A., Lisenby, K. M., Osmonson, A., 2021, Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 41(6), 526-536. doi:10.1002/phar.2527.

[2].   Virani, S. S., Alonso, A., Aparicio, H. J., et al., 2021, Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation, 143, e254-e743.

[3].   American Diabetes Association, 2021, Cardiovascular disease and risk management. Diabetes Care, 44(Suppl 1), S125-S150.

[4].   Petrie, M. C., Verma, S., Docherty, K. F., et al., 2020, Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA, 323, 1353-1368.

[5].   Zannad, F., Ferreira, J. P., Pocock, S. J., et al., 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, 396, 819-829.

[6].   Packer, M., Anker, S. D., Butler, J., et al., 2020, Cardiac and renal outcomes with empagliflozin in heart failure with a reduced ejection fraction. New England Journal of Medicine, 383, 1413-1424.